All In Biotech

NDA 021949 · Cheplapharm

Pulmicort Flexhaler

Budesonide · Inhalation · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 12, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

50,377

35,793 serious, 3,580 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

PULMICORT FLEXHALER is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Treatment of Asthma PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. Limitations of Use: PULMICORT FLEXHALER is NOT indicated for the relief of acute bronchospasm.

Mechanism: Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay. The clinical significance of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 12, 2006 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
2 products under this application
  • PULMICORT FLEXHALER · BUDESONIDE 0.08MG/INH · POWDER, METERED, INHALATION · Prescription
  • PULMICORT FLEXHALER · BUDESONIDE 0.16MG/INH · POWDER, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004527
2005584
2006585
2007775
2008909
2009722
20101,068
20111,577
20121,994
20131,341
20141,610
20151,660
20161,859
20171,985
20182,525
20193,199
20203,777
20213,988
20224,322
20234,241
20244,186
20254,065
20262,875

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pulmicort Flexhaler (Budesonide)

2024 spending

$38.9M

Beneficiaries

47,043

121,500 claims

Per beneficiary

$826

$237.59 per unit

View as table
YearSpending
2020$54,374,870
2021$52,166,128
2022$46,912,011
2023$41,825,351
2024$38,853,011

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.